What is Ketamine?
Chemical Classification
Ketamine (RS-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one) is a dissociative anesthetic and NMDA receptor antagonist. Its IUPAC name is 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one. It exists as two enantiomers: S-ketamine (esketamine) and R-ketamine, with the S form being approximately twice as potent as an anesthetic. The racemic (50:50) mixture is what's typically found in pharmaceutical and recreational contexts.
| Property | Value |
|---|---|
| Class | Dissociative anesthetic, NMDA antagonist |
| Chemical formula | C₁₃H₁₆ClNO |
| Molecular weight | 237.73 g/mol |
| CAS number | 6740-88-1 (racemate) |
| Metabolism | Hepatic (CYP2B6, CYP3A4) → norketamine → dehydronorketamine |
| Half-life (plasma) | 2–3 hours |
| Protein binding | ~47% |
| Solubility | Highly water soluble |
History
Ketamine was first synthesized in 1962 by Dr. Calvin Stevens at Parke-Davis pharmaceutical company as part of a search for safer anesthetics than phencyclidine (PCP). Clinical trials in humans began in 1964, and it received FDA approval in 1970 under the brand name Ketalar®.
It saw extensive use as a battlefield anesthetic during the Vietnam War due to its ability to produce anesthesia without suppressing respiration — crucial in trauma settings where airway management is limited. In 1985, the World Health Organization added ketamine to its List of Essential Medicines, where it remains today, making it one of the most important medications globally.
Recreational use emerged in the 1970s–80s through works like John Lilly's The Scientist (1978) and Marcia Moore's Journeys into the Bright World (1978). The 1990s saw it enter club culture as "Special K." Since the 2000s, its potential as an antidepressant has revolutionized psychiatric research.
Medical Uses
- Anesthesia: Primary use globally — induction and maintenance of anesthesia, especially in resource-limited settings and pediatric care. Unique advantage: maintains protective airway reflexes and respiratory drive.
- Treatment-Resistant Depression (TRD): IV ketamine infusions produce rapid (within hours) antidepressant effects in ~50–70% of patients who haven't responded to traditional antidepressants. Esketamine (Spravato®) nasal spray was FDA-approved for TRD in 2019.
- Chronic Pain: Used for complex regional pain syndrome (CRPS), neuropathic pain, and opioid-sparing analgesia. Sub-anesthetic infusions can provide weeks of pain relief.
- Suicidality: Rapidly reduces acute suicidal ideation, sometimes within hours. Research ongoing on mechanism and duration of effect. (Murrough et al., JAMA Psychiatry 2015)
- PTSD: Emerging research suggests benefit; several clinical trials ongoing.
- Status Epilepticus: Used when other treatments fail to control refractory seizures.
- Procedural Sedation: Especially in emergency medicine and pediatrics for painful procedures (fracture reduction, laceration repair).
How It Works in the Brain
Ketamine's primary mechanism is non-competitive antagonism of NMDA (N-methyl-D-aspartate) receptors — a class of glutamate receptors that are critical for synaptic plasticity, learning, and consciousness. It blocks these receptors by entering the channel when it's open (called "open-channel block").
Additional mechanisms include:
- AMPA receptor potentiation: Downstream glutamate signaling via AMPA receptors is enhanced; this activates BDNF (brain-derived neurotrophic factor) pathways that promote new synaptic connections — the likely basis for lasting antidepressant effects. (Autry et al., Nature 2011)
- mTOR activation: Stimulates protein synthesis in prefrontal cortex neurons, restoring synaptic connections lost through chronic stress and depression. (Li et al., Science 2010)
- Default Mode Network (DMN) disruption: Ketamine disrupts the DMN — the brain's "self-referential" resting network associated with rumination and the sense of self. This correlates with the dissociative experience and may underlie therapeutic benefits.
- Opioid receptor activity: Some studies suggest weak opioid receptor agonism, though this is not the primary mechanism and is contested.
- Sigma receptor activity: Binds sigma-1 receptors, which modulate pain and mood.
- HCN channel blockade: Contributes to anesthetic and analgesic effects.
Key reference: Zanos et al., "Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms." Pharmacological Reviews, 2018.
Forms & Dosing
Available Forms
| Form | Appearance | Context | Notes |
|---|---|---|---|
| Injectable solution | Clear liquid (10–200 mg/mL vials) | Medical — IV/IM | Most common pharmaceutical form; requires refrigeration |
| Powder | White/off-white crystalline | Recreational (evaporated from liquid) | Pharmaceutical liquid evaporated to crystal; street form varies in purity |
| Nasal spray (Spravato®) | 84 mg esketamine device | Prescription — TRD | FDA-approved 2019; self-administered under medical supervision only |
| Tablets / troches | Compounded lozenges | Prescription — pain/depression | Sublingual absorption; prescribed by ketamine clinics |
| IV infusion | Diluted solution drip | Medical / ketamine clinics | Most controlled bioavailability; fastest onset of antidepressant effect |
Bioavailability by Route
| Route | Bioavailability | Onset | Peak | Duration |
|---|---|---|---|---|
| Intravenous (IV) | 100% | 30–60 sec | 1–5 min | 15–30 min (anesthetic) |
| Intramuscular (IM) | 93% | 3–5 min | 10–20 min | 30–60 min |
| Insufflated (snorted) | 45–55% | 5–15 min | 15–30 min | 45–90 min |
| Sublingual/buccal | ~30% | 10–20 min | 20–40 min | 60–120 min |
| Oral (swallowed) | ~17% | 20–30 min | 30–60 min | 90–120 min |
| Rectal | ~25% | 15–25 min | 30–45 min | 60–90 min |
Note: Bioavailability data from Peltoniemi et al., Clinical Pharmacokinetics, 2016. Duration figures reflect noticeable psychoactive effects; cognitive effects may linger longer.
Recreational Dosing — Insufflated (Snorted)
⚠️ These are reference ranges from harm-reduction literature, not recommendations. Individual sensitivity varies enormously based on body weight, tolerance, and set/setting. Always start at the low end.
Source: TripSit Factsheet, PsychonautWiki. Ranges reflect typical street powder; lab-grade and pharmaceutical ketamine will differ.
Dosing by Other Routes (Approximate Equivalents)
| Route | Threshold | Light | Common | Strong |
|---|---|---|---|---|
| IV | 0.1–0.2 mg/kg | 0.2–0.4 mg/kg | 0.4–0.75 mg/kg | 0.75–2 mg/kg |
| IM | 10–25 mg | 25–50 mg | 50–100 mg | 100–200 mg |
| Oral | 75–150 mg | 150–200 mg | 200–300 mg | 300–450 mg |
Psychological Effects
Dissociation Spectrum
Ketamine's defining characteristic is dissociation — a detachment from one's normal sense of reality, body, and identity. The experience scales with dose:
| Dose Level | Typical Experience |
|---|---|
| Threshold / Light | Mild warmth and euphoria, slight perceptual shift, enhanced music appreciation, reduced anxiety, mild analgesia |
| Common | Floating sensation, time distortion, mild visual disturbances (geometry, trails), motor impairment, feeling of lightness, disconnection from body |
| Strong | Strong dissociation, ego softening, significant visual and auditory hallucinations, difficulty communicating, profound dreamlike states |
| K-Hole | Complete disconnection from physical reality, full ego dissolution, inability to move or speak (while conscious), intense visual/conceptual "other worlds" |
The K-Hole
The "K-hole" refers to the experience of ketamine-induced extreme dissociation — a state where a person is conscious but completely disconnected from external reality. It's typically entered at higher doses (200+ mg insufflated in a tolerant user, or lower in a naive user).
People describe the K-hole as: falling through infinite space, becoming one with the universe, encountering geometric structures or entities, loss of sense of time, identity, and bodily existence, and emergence of memories or emotional states in a non-narrative form.
Antidepressant Properties
Ketamine's antidepressant effects are among the most significant psychiatric discoveries in decades. Key findings:
- A single IV infusion (0.5 mg/kg over 40 min) produces antidepressant effects in 50–70% of treatment-resistant patients, often within 2–24 hours. (Berman et al., Biological Psychiatry 2000; Murrough et al., Archives of General Psychiatry 2012)
- Effects typically last 1–2 weeks with a single treatment; repeated infusions extend duration.
- Mechanism likely involves rapid synaptogenesis in prefrontal cortex via BDNF/TrkB/mTOR pathways. (Li et al., Science 2010)
- Esketamine (Spravato®) nasal spray is FDA-approved for treatment-resistant depression (2019) and major depressive disorder with acute suicidality (2020).
- Reduces suicidal ideation rapidly — significant in acute crisis contexts. (Murrough et al., JAMA Psychiatry 2015)
Psychedelic and Mystical Experiences
At higher doses, ketamine can produce experiences qualitatively similar to classical psychedelics (psilocybin, LSD) — including ego dissolution, mystical-type experiences, vivid visions, and profound emotional processing. Several studies suggest the intensity of the psychedelic experience correlates with antidepressant outcomes. (Dore et al., Journal of Psychoactive Drugs 2019)
Some users report lasting positive changes in perspective, values, and sense of meaning following K-hole or strong experiences — similar to reports from classical psychedelic sessions. However, unlike classical psychedelics, ketamine has a significant addiction potential (see below).
Set and Setting
The importance of set (mindset, emotional state, intentions) and setting (physical environment, people present, comfort) cannot be overstated for ketamine experiences. Factors that improve outcomes:
- Being in a comfortable, safe physical environment
- Having a trusted sober companion present
- Starting with a positive, calm emotional state
- Having intentions or a focus for the experience
- Music carefully chosen for the experience
- Integration time afterward — journaling, processing
Anxiety, chaotic environments, and social pressure to use more all increase risk of negative experiences.
Psychological Dependency
Ketamine carries meaningful potential for psychological dependency. While physical dependence is less severe than opioids or alcohol, psychological craving can be intense. Risk factors include:
- Using ketamine to cope with depression, anxiety, or trauma
- Frequent or daily use
- Using alone or in solitude
- History of other substance use disorders
- Escalating dose or frequency over time
Some heavy users develop a pattern where the gap between the high and the comedown creates a cycle of use — the pleasant dissociation becomes preferable to regular consciousness. This "k-craving" is a serious warning sign requiring professional support.
Prolonged heavy use can also cause persistent cognitive impairments in working memory, episodic memory, and executive function. (Morgan & Curran, Addiction 2012)
Physical Effects
Short-Term Physical Effects
| Effect | Mechanism | Clinical Significance |
|---|---|---|
| Analgesia | NMDA antagonism, descending pain pathways | Therapeutic — reduces pain perception |
| Increased heart rate (tachycardia) | Sympathomimetic — increases catecholamine release | Avoid if cardiac history |
| Increased blood pressure | Sympathetic activation | Contraindicated in hypertension |
| Nausea/vomiting | Not fully understood; likely vestibular + CNS | Aspiration risk when dissociated — serious |
| Nystagmus | NMDA blockade in brainstem | Involuntary rapid eye movement; benign but visible |
| Motor impairment / ataxia | CNS depression, proprioceptive disruption | Fall risk; never drive |
| Salivation increase | Sympathomimetic effect | Aspiration risk — important in medical setting |
| Mild bronchodilation | Beta-2 adrenergic stimulation | Can be beneficial in asthma |
| Respiratory depression | Dose-dependent — minimal at recreational doses | Significant at anesthetic doses; dangerous with CNS depressants |
| Dissociation / anesthesia | Primary mechanism | Dose-dependent — from mild to full anesthesia |
⚠️ Bladder Toxicity — The #1 Long-Term Risk
What is it? Repeated ketamine exposure can cause progressive inflammation and fibrosis of the bladder wall, leading to a dramatically reduced bladder capacity. In severe cases, the bladder shrinks to under 10% of normal capacity.
Symptoms:
- Frequent, urgent need to urinate (sometimes every 5–15 minutes)
- Severe lower abdominal/pelvic pain ("k-cramps")
- Blood in urine (hematuria)
- Burning or pain during urination
- Incontinence
- Upper tract involvement (hydronephrosis, kidney damage) in severe cases
Mechanism: Ketamine and its metabolites (particularly norketamine) are excreted via the urinary tract and appear to directly damage urothelial cells. The exact mechanism is still under investigation but likely involves direct cytotoxicity, neurogenic inflammation, and possible ischemia. (Chu et al., BJU International 2008; Wood et al., European Urology 2011)
Risk factors:
- Frequency of use (daily/near-daily use dramatically increases risk)
- Total cumulative dose over time
- Duration of heavy use (symptoms often appear after 1–3 years of heavy use, but can occur sooner)
- Route (oral may be higher risk than IV due to urinary metabolite concentration)
Prevention:
- ✅ Limit use frequency — take extended breaks (weeks to months between sessions)
- ✅ Stay well hydrated before, during, and after use
- ✅ Stop immediately if urinary symptoms develop
- ✅ See a urologist promptly if symptoms appear — early cessation can allow recovery
Liver Effects
Chronic ketamine use, particularly at high doses, can cause ketamine-associated biliary disease (KABD) — inflammation of the bile ducts (cholangiopathy) and liver enzyme elevations. This is distinct from alcohol-related liver disease and poorly understood.
- Symptoms: abdominal pain (particularly right upper quadrant), jaundice, elevated liver enzymes
- Typically reversible with cessation
- Severe cases have required liver transplantation in case reports
Reference: Lo et al., "Ketamine abusers had significantly more biliary complications." Hong Kong Medical Journal, 2011.
Respiratory Effects
This is where ketamine differs from most anesthetics — it has a much better respiratory safety profile at typical recreational doses:
- At doses used recreationally (up to ~300 mg insufflated), respiratory depression is mild
- Protective laryngeal reflexes are largely preserved (unlike classical anesthetics) — but this is NOT reliable protection
- At anesthetic doses (IV induction doses), significant apnea can occur
- Major danger: Combining with CNS depressants (alcohol, opioids, GHB, benzodiazepines) dramatically increases respiratory depression risk — this interaction has killed people
Tolerance Development
Tolerance to ketamine's dissociative and euphoric effects develops rapidly — often within weeks of regular use. This means users need progressively higher doses to achieve the same effect, accelerating bladder/liver damage and psychological dependence. Tolerance is route-dependent but all routes can produce it.
Cross-tolerance with other NMDA antagonists (e.g., DXM, PCP) exists but is incomplete.
Addiction and Withdrawal
Ketamine is considered to have moderate addiction potential — lower than alcohol, opioids, or stimulants but not trivial. It is Schedule III in the US (accepted medical use, moderate potential for abuse).
Withdrawal symptoms (with heavy, frequent use):
- Anxiety, agitation, dysphoria
- Intense cravings
- Insomnia
- Depression (particularly pronounced — K's antidepressant effect wears off and baseline depression may rebound worse)
- Physical symptoms are generally mild: chills, sweating, loss of appetite
- Cognitive cloudiness ("brain fog")
Unlike alcohol or benzodiazepines, ketamine withdrawal is not medically dangerous but can be intensely uncomfortable. Support and medical assistance are recommended for heavy users stopping abruptly.